Serotonin News and Research

Latest Serotonin News and Research

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Women with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death, concludes a study published on bmj.com today.

10 Feb 2010

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

7 Feb 2010

Study suggests molecules and pathways in mood regulation and circadian rhythms are intertwined

Scientists at Emory University School of Medicine have discovered unexpected properties for a precursor to melatonin, the hormone that regulates sleep cycles.

5 Feb 2010

New class of compound could become effective antidepressant with minimal side effects

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world.

5 Feb 2010

Sudden infant death syndrome linked to low serotonin levels

Taking the next step in more than 20 years of research, researchers at Children's Hospital Boston have linked sudden infant death syndrome (SIDS) with low production of serotonin in the brainstem, based on a comparison of brainstem samples from infants dying of SIDS compared to brainstems of infants dying from other, known causes.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.

3 Feb 2010

Decreased levels in brainstem of serotonin associated with increased risk for SIDS

Preliminary research indicates that decreased levels in the brainstem of serotonin (5-hydroxytryptamine [5-HT]; a neurotransmitter involved in several brain functions) and tryptophan hydroxylase (TPH2; an enzyme involved in the synthesis of serotonin) are associated with an increased risk for sudden infant death syndrome (SIDS), according to a study in the February 3 issue of JAMA.

3 Feb 2010

Evidence suggests antidepressants may improve post-stroke recovery

Patients who received the antidepressant escitalopram following a stroke appeared to recover more of their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Feb 2010

Safe natural extracts reduce hunger and help control appetite

Klaumwell Research Labs, LLC, U.S., a subsidiary of Italian multinational Medestea Internazionale, announced positive results from a double-blind, placebo-controlled clinical study published in the prestigious, peer-reviewed International Journal of Obesity which demonstrates the efficacy of key ingredients contained in a new appetite control spray. Fullfast™ is a clinically tested dietary supplement that helps reduce excessive feelings of hunger.

28 Jan 2010

Women on antidepressant drugs may experience lactation difficulties

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), women taking commonly used forms of antidepressant drugs may experience delayed lactation after giving birth and may need additional support to achieve their breastfeeding goals.

27 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Study reveals link between serotonin receptor number and antidepressant treatment

An excess of one type of serotonin receptor in the center of the brain may explain why antidepressants fail to relieve symptoms of depression for 50 percent of patients, a new study from researchers at Columbia University Medical Center shows.

18 Jan 2010

Portugal life scientist awarded ERC's Advanced Investigator Grant

Zachary Mainen, coordinator of the Champalimaud Foundation Neuroscience Programme at the IGC, has become one of the most recent winners of the prestigious and highly competitive European Research Council grants, to the value of 2.3 million euro, for a period of five years. This grant, which recognises Mainen's contribution to the Neuroscience field, will be used to elucidate the biological role of the neurotransmitter serotonin.

18 Jan 2010

IGC scientist wins ERC grant for neuroscience research

18 Jan 2010

Serotonin News and Research

Latest Serotonin News and Research

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

Study suggests molecules and pathways in mood regulation and circadian rhythms are intertwined

New class of compound could become effective antidepressant with minimal side effects

Sudden infant death syndrome linked to low serotonin levels

Study shows Cymbalta reduces chronic low back pain

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Decreased levels in brainstem of serotonin associated with increased risk for SIDS

Evidence suggests antidepressants may improve post-stroke recovery

Safe natural extracts reduce hunger and help control appetite

Women on antidepressant drugs may experience lactation difficulties

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Study reveals link between serotonin receptor number and antidepressant treatment

Portugal life scientist awarded ERC's Advanced Investigator Grant

IGC scientist wins ERC grant for neuroscience research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Serotonin News and Research

Latest Serotonin News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in